longer term outcomes with pembrolizumab plus axitinib for advanced rcc
Published 3 years ago • 240 plays • Length 4:17Download video MP4
Download video MP3
Similar videos
-
3:26
extended follow-up from a trial of pembrolizumab plus axitinib for advanced renal cell carcinoma
-
2:31
axitinib plus pembrolizumab in advanced rcc
-
5:10
real-world treatment outcomes of 1l axitinib pembrolizumab in patients with advanced rcc in the us
-
8:50
updated results of a clinical trial evaluating pembrolizumab axitinib for frontline adv rcc
-
1:00
pembrolizumab/axitinib and avelumab/axitinib combo for rcc
-
3:30
promising results for axitinib and pembrolizumab in advanced renal cell cancer
-
2:18
pembrolizumab monotherapy and pembro-axitinib for rcc
-
1:29
phase i/ii study of nivolumab and axitinib for advanced rcc
-
1:17
dr. vaishampayan on axitinib plus pembrolizumab in advanced rcc
-
4:40
pembrolizumab plus axitinib in the second-line and beyond for mrcc
-
10:06
lenvatinib and pembrolizumab compared to sunitinib for advanced renal cell carcinoma
-
1:40
dr. powles on fda approval of pembrolizumab plus axitinib in advanced rcc
-
3:28
dr rini on a biomarker analysis for pembrolizumab/axitinib in advanced rcc
-
1:45
keynote-426: pembrolizumab and axitinib vs sunitinib in advanced renal cell carcinoma
-
1:06
exciting potential of pembrolizumab combined with axitinib for kidney cancer
-
2:23
overview of a phase iii trial of pembrolizumab plus axitinib in rcc
-
2:06
updated analysis of keynote-426: pembro plus axitinib vs sunitinib in mrcc
-
2:32
avelumab plus axitinib improves survival in advanced renal-cell carcinoma patients
-
2:35
key data from asco gu 2019 on mrcc: pembrolizumab and axitinib as first-line therapy